by qfrsolutions | Oct 17, 2016 | News
Source: Globe Newswire Journey Medical Corporation, a Fortress Biotech, Inc. (FBIO) company, launched Targadox™ (doxycycline hyclate USP) 50 mg film coated tablets indicated as adjunctive therapy for the treatment of severe acne. Targadox™ is the only 50...
by qfrsolutions | Oct 12, 2016 | News
Source: Playing catch-up in the next-gen psoriasis market, Eli Lilly is going all out with its first ad campaign for Taltz, promising “a chance at completely clear skin.” In Lilly’s crosshairs? Novartis’ Cosentyx, which has had a 14-month lead...
by qfrsolutions | Oct 4, 2016 | News
Source: Bloomberg Samsung Biologics Co. is seeking to raise as much as 2.25 trillion won ($2 billion) from a South Korean initial public offering, taking an important step toward its goal of becoming the world’s largest contract manufacturer of biological...
by qfrsolutions | Sep 21, 2016 | News
Source: WRAL TechWire Durham-based Novan goes public at $11 a share – and its stock shows plenty of “pop,” surging more than 70 percent just ahead of the market close Wednesday. Novan priced its IPO at about $44 million, down from an earlier target...
by qfrsolutions | Sep 16, 2016 | News
Source: Allergan PLC agreed to acquire clinical-stage biotechnology company Vitae Pharmaceuticals Inc. for $639 million, more than double its market value, in a move aimed at strengthening the drugmaker’s skin-care pipeline. The price values Vitae at $21 a...
by qfrsolutions | Sep 12, 2016 | News
Source: Horizon Pharma Plc (HZNP.O) said it would buy Raptor Pharmaceutical Corp (RPTP.O) for nearly $800 million to bolster its portfolio of drugs to treat rare diseases and reduce its dependence on the primary care market. The deal will give Horizon drugs used to...
